<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141048</identifier>
<setSpec>0033-8338</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Usefulness of cognitive targeting in multiparametric MRI-guided biopsy to diagnose the dominant lesion in prostate cancer</dc:title>
<dc:description xml:lang="en">Objective. To evaluate the safety and efficacy of cognitive targeting in multiparametric MRI-guided biopsy to obtain samples of the dominant nodule in prostate cancer. Material and methods. We performed cognitive-targeted biopsy after multiparametric MRI in 53 patients with progressive elevation of PSA. All patients provided written informed consent. Biopsies were done via a transperineal route under ultrasound guidance. The first three samples were obtained by cognitive targeting, with the target lesion determined by multiparametric MRI according to the PI-RADS (prostate imaging, reporting, and data system) criteria. Then 9 cylinders were obtained from the remaining segments of the prostate (systematic biopsies). The pathologist evaluated the 12 cylinders without knowing which ones were obtained by cognitive targeting. In patients with multifocal lesions, we defined the dominant lesion as the one with the highest Gleason score and tumor volume; in patients with unifocal lesions, we defined the dominant lesion as the lesion identified. Results. We diagnosed 29 prostate tumors. In 89.7% (26/29), the dominant nodule was diagnosed by the cognitive-targeted biopsy. If only cognitive-targeted biopsy had been done, the dominant nodule would not have been diagnosed in two (3.8%, 2/53) patients and only one (1.8%, 1/53) patient, in whom no sample was obtained from the lesion with the highest Gleason score, would have been understaged. The rate of positivity of cognitive-targeted biopsy was 50.9% (27/53) in the entire group of patients and 46.3% (19/41) in the group of patients with previous negative biopsies. No significant immediate or late complications were observed. Conclusion. Cognitive targeting is safe and efficacious for detecting the dominant lesion in prostate cancer (AU)</dc:description>
<dc:creator>Serrano Alcalá, E</dc:creator>
<dc:creator>Abreu De Con, JA</dc:creator>
<dc:creator>Hurtado Salom, C</dc:creator>
<dc:creator>Rebenaque, E</dc:creator>
<dc:creator>Conejero Olesti, A</dc:creator>
<dc:creator>Parada, D</dc:creator>
<dc:creator>Garcia Bennett, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Evaluar la seguridad y eficacia de la biopsia guiada cognitivamente (BGC) con la resonancia magnética multiparamétrica (RMmp) para obtener muestras del nódulo dominante del cáncer de próstata. Material y métodos. Realizamos una BGC en 53 pacientes por elevación progresiva del PSA tras hacer una RMmp. Todos los pacientes firmaron el consentimiento informado. Las biopsias se realizaron por vía transperineal con control ecográfico. Las 3 primeras muestras se obtuvieron de la lesión diana determinada por la RMmp, utilizando criterios PIRADS (corresponden a las BGC). Posteriormente se obtuvieron 9 cilindros del resto de los segmentos de la próstata (biopsias sistemáticas). El anatomopatólogo valoró los 12 cilindros sin saber cuáles correspondían a las BGC y cuáles a las biopsias sistemáticas. Definimos como lesión dominante la de mayor valor Gleason y volumen tumoral en lesiones multifocales y a la única lesión detectada en tumores unifocales. Resultados. Diagnosticamos 29 tumores de próstata. En el 89,7% (26/29), el nódulo dominante fue diagnosticado por las BGC. De haber realizado únicamente las BGC no se hubieran diagnosticado 2 pacientes (3,8%, 2/53) y se hubiera infraestadificado solo uno (1,8%, 1/53) en el que no se obtuvo muestra de la lesión con mayor valor Gleason. La tasa de positividad de la BGC fue del 50,9% (27/53), y en los pacientes con biopsias previas negativas del 46,3% (19/41). No observamos complicaciones significativas inmediatas ni tardías. Conclusión. La BGC es una técnica segura y eficaz para detectar la lesión dominante del cáncer de próstata (AU)</dc:description>
<dc:source>Radiología (Madr., Ed. impr.);57(5): 428-433, sept.-oct. 2015. tab, ilus</dc:source>
<dc:identifier>ibc-141048</dc:identifier>
<dc:title xml:lang="es">Utilidad de la biopsia guiada cognitivamente por resonancia magnética multiparamétrica para diagnosticar la lesión dominante del cáncer de próstata</dc:title>
<dc:subject>^d55010^s22048</dc:subject>
<dc:subject>^d22935^s22045</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d55010^s22066</dc:subject>
<dc:subject>^d11914^s29166</dc:subject>
<dc:subject>^d55010^s22045</dc:subject>
<dc:subject>^d23405^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d55010^s22074</dc:subject>
<dc:subject>^d50302</dc:subject>
<dc:subject>^d55010^s22039</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201510</dc:date>
</metadata>
</record>
</ibecs-document>
